Champoux Jennifer 4

What Happened
Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics (GLUE), exercised 2,175 stock options on May 27, 2026 by paying $3.98 per share (total cost ~$8,657) and immediately sold those 2,175 shares in the open market at $20.00 per share for proceeds of $43,500. The filing also shows the related derivative instrument was disposed of (common when options are exercised and converted to shares).

Key Details

• Transaction date: May 27, 2026; Form 4 filed May 28, 2026 (appears timely).
• Exercise: 2,175 shares acquired at $3.98 each; total cash paid ~$8,657.
• Sale: 2,175 shares sold at $20.00 each; total proceeds $43,500.
• Derivative entry: 2,175 option units shown as disposed at $0 (reflects conversion/exercise).
• Plan note: Transactions were made under a Rule 10b5‑1 trading plan adopted by Champoux on Feb 19, 2026.
• Vesting: 25% of the option vested May 28, 2025; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context
This was an exercise-and-sell sequence (often called a cashless or sell-to-cover style): the insider converted options into shares and sold those shares the same day. Sales executed under a pre-established 10b5‑1 plan are typically scheduled in advance and are treated as routine trading rather than a discretionary trade made in response to new company information.